Stigmatisation and body image impairment in dermatological patients: protocol for an observational multicentre study in 16 European countries by Dalgard, F.J. et al.
1Dalgard FJ, et al. BMJ Open 2018;8:e024877. doi:10.1136/bmjopen-2018-024877
Open access 
Stigmatisation and body image 
impairment in dermatological patients: 
protocol for an observational multicentre 
study in 16 European countries
Florence J Dalgard,1,2 Anthony Bewley,3 Andrea W Evers,4 Uwe Gieler,5 Lars Lien,2 
Francesca Sampogna,6 Sonja Ständer,7 Lucia Tomas-Aragones,8 Ninke Vulink,9 
Jörg Kupfer10
To cite: Dalgard FJ, Bewley A, 
Evers AW, et al.  Stigmatisation 
and body image impairment 
in dermatological patients: 
protocol for an observational 
multicentre study in 16 
European countries. BMJ Open 
2018;8:e024877. doi:10.1136/
bmjopen-2018-024877
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2018- 
024877). 
Received 16 July 2018
Revised 9 September 2018
Accepted 28 September 2018
For numbered affiliations see 
end of article.
Correspondence to
Dr Florence J Dalgard;  
 florikje@ gmail. com
Protocol
© Author(s) (or their 
employer(s)) 2018. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
AbstrACt
Introduction Patients with common skin diseases may 
have substantial psychosocial comorbidity and reduced 
quality of life. This study aims at exploring further the 
psychosocial burden of skin diseases by assessing 
stigmatisation and body image problems in a large sample 
of patients with skin disease across Europe.
Methods and analysis The study is an observational 
cross-sectional multicentre study across 16 European 
countries comparing stigmatisation and body image 
in patients with skin disease compared with controls. 
Consecutive patients will be recruited in outpatient clinics 
and will complete validated questionnaires prior to clinical 
examination by a dermatologist at each recruitment site. 
In addition to sociodemographic background information, 
the outcomes will be: mood disorders assessed by 
short versions of the Patient Health Questionnaire and 
the General Anxiety Disorder Assessment; general 
health assessed by the EuroQol-Visual Analogue Scale; 
stigmatisation experience assessed by the Perceived 
Stigmatisation Questionnaire; stress assessed by the 
Perceived Stress Scale and body image assessed by the 
Dysmorphic Concern Questionnaire. The main criteria for 
eligibility are to be 18 years old or more. The analysis will 
include comparison between patients and controls for 
the main outcomes using t-tests, analyses of covariance 
and multivariate logistic regression models adjusting for 
potential confounding factors.
Ethics and dissemination The study protocol is approved 
by the University of Giessen and by the local Ethical 
Committee in each recruitment centre. Informed consent 
will be given by each participant. The results of the study 
will be disseminated by publications in international 
peer-reviewed journals and presented at international 
conferences and general public conferences. Results 
will influence support intervention and management of 
patients with skin disease across Europe.
trial registration number DRKS00012745; Pre-results.
IntroduCtIon 
The psychological impact of skin diseases is 
an issue of increasing concern worldwide.1–3 
Skin diseases are the fourth leading cause of 
non-fatal disease in the recent Global Burden 
of Disease Study 2010.3 Most skin conditions 
are non-fatal and chronic. Globally, the most 
prevalent conditions are skin infections, acne, 
pruritus and eczema.3 4 The psychosocial 
impact of common skin disease is expected 
to be large worldwide but little research 
or exploration in this area has been under-
taken. Our group has recently demonstrated, 
in far reaching publications, the psychosocial 
burden of skin conditions in 13 European 
countries by documenting the psychological 
comorbidity and the impairment on sexual 
life, attachment style and general quality of 
life in common skin diseases.5–9 
We believe that there is a requirement 
to further explore in different parts of the 
world aspects of the psychosocial burden of 
skin disease. This, we believe, will achieve 
greater knowledge and understanding of the 
aspects of living with skin disease over time 
and enable healthcare professionals to target 
appropriate intervention programmes.
stigmatisation
Patients with chronic skin disease can display 
a fear of negative evaluation and perceived 
strengths and limitations of this study
 ► The large size of this multicentre study is a strength.
 ► The multicentre study conducted in 16 countries 
across Europe will enable to explore cultural and 
gender aspects of stigmatisation and body dysmor-
phic concern in patients with skin disease.
 ► The inclusion of a control group will enable to com-
pare with a reference population.
 ► The design of the study is cross-sectional, there-
fore, it will not be possible to establish the direct 
causation of any possible association.
 ► No aspects of dermatological treatments were in-
cluded in this study.
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stigmatisation. Patients with visible skin lesions are 
reported to be more likely to have fear of social rejection 
together with fear of negative evaluation by others either 
within their peer group or from others. The perceived 
stigmatisation is best described as experiences of social 
disapproval, discrediting or devaluation based on an 
attribute or physical mark.10 Patients with chronic skin 
diseases regularly report experiences of perceived stig-
matisation, for example, others staring at them, receiving 
negative comments or avoiding physical contact.11–13
Culture, societal and other social influences appear to 
play a role in this stress experience, based on common 
misconceptions, for example, that skin diseases are conta-
gious or a consequence of poor hygiene.14 It is known that 
perceived stigmatisation experiences are common among 
patients with chronic diseases.11–13 In addition, perceived 
stigmatisation is higher when physical and psycholog-
ical well-being and functioning in daily life is reduced, 
for example, in patients with chronic skin diseases, such 
as atopic dermatitis and psoriasis.13 15–17 When consid-
ering interindividual differences, research in psoriasis 
patients indicated that younger patients, those who have 
no partner, those with a lower educational level as well as 
patients who may experience higher levels of social inhi-
bition and negative affectivity might be more affected by 
this experience of perceived stigmatisation.15
Finally, stigmatisation may also affect other areas of 
functioning other than only the self-reported well-being 
of the patients. For example, a stigmatisation-related 
implicit bias regarding the disgust reactions of others has 
recently been shown in patients with chronic skin condi-
tions of psoriasis.18 A more systematic research of stigma-
tisation among patient groups can produce an important 
insight into the possible social and cultural difference of 
stigmatisation experience in patients with skin diseases. 
This will enable healthcare professionals to finally develop 
screening and intervention procedures to better support 
patients in coping with these stigmatisation experiences.
body image disorders
Dissatisfaction with the body or the skin is common. Most 
people are not fully satisfied with their body appearance 
or their skin but accept and live with the realisation that 
their body is imperfect. The influence of culture and 
ethnicity might be important aspects of body satisfaction.
For some, the degree of dissatisfaction is so high that it 
culminates in a preoccupation with a perceived defect of 
their body which interferes dramatically with their daily life 
and routine. This is known as body dysmorphic disorder 
(BDD). BDD is a recognised psychiatric condition and 
categorised as part of the obsessive–compulsive and related 
disorders in the latest edition of the Diagnostic and Statis-
tical Manual of Mental Disorders.19 The condition occurs 
in around 2% in the general population in the developed 
world and recent data suggest that this occurrence could be 
increasing.19–22 The prevalence is varying in different patient 
settings and, among dermatological patients, the prevalence 
is estimated to be at least 11%.21 23
BDD is a distressing condition which can be connected 
to any part of the body and often linked to shame. Depres-
sion, social anxiety and suicidal ideation are frequently 
comorbidities. In addition, there is a higher rate of 
suicide among patients with BDD.24 25
Persons with BDD frequently consult a dermatologist 
but are rarely seen by a psychiatrist or mental health 
specialist. Patients with BDD are often dissatisfied with 
their treatment and ‘doctor shop’. They are convinced 
that their problem is physical and not mental. Also, 
patients with BDD consume substantial resources in 
healthcare systems and are challenging to help.19 There-
fore, it is important for the clinicians to understand when 
the patient is suffering from the condition in order to 
provide adequate treatment and also to be able to distin-
guish the BDD condition from the more trivial condition 
of dissatisfaction with body.
the psychosocial burden of skin disease
The primary objective of the present study is to describe 
the psychosocial burden of skin diseases by assessing the 
experience of stigmatisation of patients with common skin 
disease and by estimating the prevalence of body image 
disorder in patients with skin disease. The secondary 
objective is to compare this burden in different countries 
across Europe.
MEthods And AnAlysIs
setting
The study is an observational cross-sectional multicentre 
study across 16 European countries comparing stigma-
tisation and body image in patients with skin disease 
compared with controls. Patients will be recruited from 
public general dermatological outpatient clinics at each 
participating centre. The study will be organised following 
the time table (table 1) and conducted by members of 
the European Society for Dermatology and Psychiatry. 
The dermatological departments of the following institu-
tions have signed an agreement to participate: University 
of Graz (Austria), University of Copenhagen, Roskilde 
Hospital (Denmark), Brest University (France), Justus 
Liebig University, Giessen (Germany), Muenster Univer-
sity (Germany), University of Szeged (Hungary), Istituto 
Dermopatico dell’Immacolata, Rome (Italy), Skopje 
University (Macedonia), University of Leiden, Radboud 
University of Nijmegen, University of Amsterdam (Neth-
erlands), University of Stavanger, Innlandet Hospital 
Trust (Norway), Wroclaw University, University of Rzeszow 
(Poland), University of Coimbra (Portugal), First Moscow 
State Medical University, Moscow Scientifica and Prac-
tical Centre for Dermatology and Cosmetology (Russia), 
Alcaniz Hospital, Alcaniz, Department of dermatology, 
Zaragosa, Hospital of Barbastro, Huesca, Aragon (Spain), 
Skåne University Hospital, Malmö, Lund University 
(Sweden), Sisli Etfal Hospital, Istanbul (Turkey), Barts 
Health National Health Service Trust London, Sheffield 
University, Cardiff University (UK).
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Procedure
Recruitment of cases will take place at the general 
dermatological outpatient clinic at each centre in each 
participating country in the same way as described in 
the previous study.5 From the previous study, we expect 
that the most common skin diseases will be: psoriasis, 
non-melanoma skin cancers, infections of the skin, 
non-classified eczema and acne. Consecutive patients 
will be invited to participate in the study on one or 
more random days until the required number of 250 
respondents is reached. All patients will be fully briefed 
by a research assistant and will be accepted onto the 
study by signing a written consent form. Each patient 
will be examined by a dermatologist who will record the 
diagnosis; and, if required any secondary diagnosis will 
be recorded. The recruitment of 125 controls at each 
centre will be completed by announcement among the 
staff in the hospital institution.
Inclusion and exclusion criteria
Eligible patients and controls must be 18 years old 
or more and able to read and write the language of 
the questionnaire. Exclusions include patients unable 
to read the questionnaires in available languages, 
and, for controls, people with a skin condition under 
treatment.
Assignment
All consecutive patients on specific days in the general 
dermatology clinics will be approached. Randomisa-
tion is therefore unnecessary for this study design. The 
drop-out rate will be recorded (noting age and gender) 
and reasons why they do not wish to participate.
outcome measures
Clinical assessment of patients
The dermatologist making the diagnosis will objec-
tively evaluate and record International Classification of 
Disease 10th revision (ICD-10) diagnose for each condi-
tion. The severity will be assessed as ‘mild’, ‘moderate’ or 
‘severe’. The presence of other conditions including the 
following treated comorbidities will be recorded: cardio-
vascular disease, chronic respiratory disease, diabetes and 
rheumatological disease. Clinicians will also be required 
to answer questions on whether signs of depression, 
anxiety and feelings of dysmorphic concern are present 
in the patient.
Self-reported measures
A background questionnaire (online supplementary 
appendix) will be filled in by patients and controls and 
provide information on sociodemographics including 
income, education, employment and disease characteris-
tics such as duration and localisation of skin disease. Data 
on comorbidities, weight and height, presence of pruritus 
and its characteristics will also be recorded. Data on 
suicidal ideation will be collected in the same way as the 
previous study5 with the item ‘Did you ever have suicidal 
ideation?’ Patients only will give information on severity 
of their skin condition, age of onset and localisation of 
the skin disease.
Scales
Wherever possible, we have chosen validated scales 
that were adapted and translated to most European 
languages to minimise the back-translation workload. 
Those scales that were not previously translated were 
back translated following instructions for cultural 
adaptation for the Dermatology Life Quality Index 
http:// sites. cardiff. ac. uk/ dermatology/ quality- of- life/ 
dermatology- quality- of- life- index- dlqi/.
Mood disorders are to be assessed by
The Patient Health Questionnaire-2: a validated question-
naire with two items assessing depression. The General 
Anxiety Disorder Assessment-2: a validated instrument 
with two items assessing anxiety. The two scales have solid 
psychometric properties and are used in different patient 
populations.26 They are translated and culturally adapted 
to many languages (http://www. phqscreeners. com). 
Both short versions have a range from 0 to 6 and have 
a cut-off value ≥3 with sensitivity and specificity values 
about 0.85 and Cronbach’s alpha about 0.83.
Quality of life is to be assessed by
Self-reported Health State: EuroQol-five dimension-Vi-
sual Analogue Scale (VAS): a standardised generic instru-
ment assessing general health state9 with a VAS assessing 
the health state, from ‘0’ to ‘100’ (worst to best imagin-
able health state). This scale is used in different medical 
conditions and because of existing population norms 
is prized by health economists.27 Recently its utility in 
Table 1 Study dates
Action Study dates
Involved 
colleagues
Ethical committee March–June 2017 Working group
Submission study 
proposal
Dec 2016–August 2017 Working group
Invitation centres October–January 2017
Translation 
questionnaires
March–September 2017 All
Study agreement May–June 2017 All
Data collection September 2017–
September 2018
All
Data cleaning September 2018–
December 2018
Giessen
Data analysis January 2019–April 
2019
Jörg Kupfer 
and Florence 
Dalgard 
First article May–November 2019 All
Following articles January 2020–January 
2022
All
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dermatology was demonstrated in a multicentre study 
among dermatological patients across Europe.6
Stigmatisation is to be assessed by
Perceived Stigmatisation Questionnaire: a generic instru-
ment with 21 items assessing perceived stigmatisation and 
social experience in people with visible difference. The 
good reliability and validity of the scale have been demon-
strated among patients with scars.28
Stress is to be assessed by
Perceived Stress Scale29 30: a 10-item questionnaire 
assessing perceived stress with solid psychometric prop-
erties widely used in different settings, translated and 
cultural adapted to many languages.29 31
BDD is to be assessed by
Dysmorphic Concern Questionnaire: a 7-item scale 
assessing body image concern that has the advantage that 
it can be used among patients and controls as well. It has 
been shown to be a sensitive and specific screening instru-
ment for BDD.32
Proposed analysis
Before the data collection starts, a back-translation 
process of the questionnaires will be done by each centre 
in the languages for whom the translation is not available. 
The back translations will be forwarded to the Statistical 
Centre (Institute of Medical Psychology, University of 
Giessen, Germany) to enable a standardised checking 
procedure for the identical sets of questionnaires. After 
collection, the data will be checked and entered in an 
SPSS or Excel database at each site. The final corrected 
data will be sent to the statistical centre. Data will be 
merged into a single file and rechecked and cleaned. 
SPSS V.24 software will be used to analyse the data. All 
diagnoses will be categorised in groups adapted from a 
previous study.5 33 The largest groups of skin diseases like 
psoriasis, acne and atopic dermatitis will be defined. To 
characterise the study population, we will report numbers 
and percentages for categorical variables, and mean 
values with SD for continuous variables.
To compare patients and controls for perceived stig-
matisation, t-tests and analyses of covariance (ANCOVAs) 
will be calculated adjusting for the following potential 
confounding factors: sociodemographic variables, anxiety, 
depression, overall health state and perceived stress. To 
compare the risk for BDDs between the patients and 
controls, we will use the X2 test for dichotomous variables. 
Multivariate logistic regression models will be tested to 
study the associations between the main outcome variable 
‘risk for BDDs’ and groups (patients/controls). As a first 
step we will calculate the crude ORs and in the second 
adjusted OR simultaneously controlling for potential 
confounding factors (same as for ANCOVAs). The OR 
will be calculated from the estimated regression coeffi-
cients B from the logistic regressions.
Patient and public involvement
In a pilot study, the research questions were discussed 
with patients and their point of views about stigmatisation 
were taken into the study design. The Norwegian patient 
society ‘the Psoriasis and Eczema Forbundet’ (PEF) was 
involved in a discussion of the study design and fully 
accepted the proposals of the study group. The society 
was not involved in the recruitment of the study. We plan 
to send our results to our patient society, PEF, as well 
to other patient organisation in the countries who are 
participating in the study.
The study is not a randomised controlled trial and the 
questionnaires are routine assessments which normally 
do not impact subjects apart from the time commitment. 
We plan to acknowledge the PEF in future publications.
Ethics and dissemination
The study will be conducted in accordance with the 
Declaration of Helsinki. A study agreement has been 
signed by all participating colleagues in the study. All 
eligible patients and controls will be informed verbally 
and in writing of the purpose of the study, the expected 
duration and procedure, the right to decline to partic-
ipate and to withdraw from the research, without any 
consequences, at any given time once participation has 
commenced. The results will be disseminated by publica-
tion in international peer-reviewed journals and presenta-
tions at national and international meetings.
With this innovative study, we will expand the knowl-
edge of the psychosocial burden of common skin diseases 
in patients from different countries in and outside 
Europe, and specifically address the burden of stigmatisa-
tion of patients with dermatological disorders.
The large scale of this study is a strength, giving a good 
power to our results, and the study group has a successful 
provenance in managing this kind of work. Nevertheless, 
we expect some limitations, for example, the distribution 
of patients might be different from one centre to another, 
even though we have aimed to standardise the setting by 
recruiting from general outpatient clinics. The recruit-
ment of controls might be challenging in some centres 
but we expect to manage this by recruiting local research 
assistant who will be supported by the study team.
The results will expand our knowledge on the psycho-
social burden of skin disease both at a population and 
at an individual level. We expect that the findings will 
have an impact on the clinical management of patients 
with skin disease, enabling dermatologists to understand 
uncovered needs of their patients to better plan appro-
priate healthcare.
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